Blood Monocyte Frequency May Be a Biomarker for Response to Anti–PD-1

Cancer Discovery - United States
doi 10.1158/2159-8290.cd-rw2018-016
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors

Unknown

Publisher

American Association for Cancer Research (AACR)

Related search

823 Biomarker Approaches for Anti-Pd-1 in Melanoma: A Meta-Analysis

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2019English

ARID1A Alterations Function as a Biomarker for Longer Progression-Free Survival After Anti-Pd-1/Pd-L1 Immunotherapy

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2020English

CD4+ T-Cell Immunity in the Peripheral Blood Correlates With Response to Anti-Pd-1 Therapy

Cancer immunology research
Cancer ResearchImmunology
2019English

Complete Response to Anti-Pd-1 Antibody Monotherapy in Metastatic Melanoma-Can Therapy Be Discontinued? A Review of Current Literature

Journal of Cancer Biology and Therapeutics
2019English

Serum miR‑22 May Be a Biomarker for Papillary Thyroid Cancer

Oncology Letters
Cancer ResearchOncology
2019English

"May Adiponectin Be Considered as a Novel Cardiometabolic Biomarker?"

Journal of Diabetes, Metabolic Disorders & Control
2014English

Circulating Tumour DNA for Monitoring Treatment Response to Anti-Pd-1 Immunotherapy in Melanoma Patients

Acta Dermato-Venereologica
DermatologyMedicine
2017English

Serum miR-21 May Be a Potential Diagnostic Biomarker for Diabetic Nephropathy

Experimental and Clinical Endocrinology and Diabetes
Internal MedicineMedicineDiabetesMetabolismEndocrinology
2015English

CTLA4 Methylation Predicts Response to Anti–PD-1 and Anti–CTLA-4 Immunotherapy in Melanoma Patients

JCI insight
Medicine
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy